DE69508463T2 - Propiophenonderivate und Verfahren zu deren Herstellung - Google Patents

Propiophenonderivate und Verfahren zu deren Herstellung

Info

Publication number
DE69508463T2
DE69508463T2 DE69508463T DE69508463T DE69508463T2 DE 69508463 T2 DE69508463 T2 DE 69508463T2 DE 69508463 T DE69508463 T DE 69508463T DE 69508463 T DE69508463 T DE 69508463T DE 69508463 T2 DE69508463 T2 DE 69508463T2
Authority
DE
Germany
Prior art keywords
glucopyranosyl
preparation
beta
propiophenone derivatives
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69508463T
Other languages
English (en)
Other versions
DE69508463D1 (de
Inventor
Kenji Tsujihara
Mitsuya Hongu
Nobuyuki Funami
Masanori Inamasu
Kenji Arakawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Seiyaku Co Ltd
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Publication of DE69508463D1 publication Critical patent/DE69508463D1/de
Application granted granted Critical
Publication of DE69508463T2 publication Critical patent/DE69508463T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
DE69508463T 1994-05-11 1995-05-11 Propiophenonderivate und Verfahren zu deren Herstellung Expired - Lifetime DE69508463T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9680594 1994-05-11
JP28234494 1994-11-17

Publications (2)

Publication Number Publication Date
DE69508463D1 DE69508463D1 (de) 1999-04-29
DE69508463T2 true DE69508463T2 (de) 1999-08-19

Family

ID=26437976

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69508463T Expired - Lifetime DE69508463T2 (de) 1994-05-11 1995-05-11 Propiophenonderivate und Verfahren zu deren Herstellung

Country Status (15)

Country Link
US (1) US5830873A (de)
EP (1) EP0684254B1 (de)
KR (1) KR100318793B1 (de)
CN (1) CN1042637C (de)
AT (1) ATE178069T1 (de)
AU (1) AU680118B2 (de)
BR (1) BR9502016A (de)
CA (1) CA2149160C (de)
DE (1) DE69508463T2 (de)
DK (1) DK0684254T3 (de)
ES (1) ES2133614T3 (de)
FI (1) FI116975B (de)
GR (1) GR3029795T3 (de)
IL (1) IL113581A (de)
MY (1) MY119134A (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
JP3059088B2 (ja) * 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
DK0850948T3 (da) * 1996-12-26 2002-07-29 Tanabe Seiyaku Co Propiophenonderivater og fremgangsmåde til fremstilling deraf
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
ATE442148T1 (de) * 2001-04-04 2009-09-15 Ortho Mcneil Janssen Pharm Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
JP4590159B2 (ja) * 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
CA2549022A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
CA2549015A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted fused heterocyclic c-glycosides
BRPI0413232B8 (pt) * 2003-08-01 2021-05-25 Mitsubishi Tanabe Pharma Corp composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto
AU2004261664A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-O-glucosides
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
CA2549017A1 (en) * 2003-08-01 2005-02-10 Mona Patel Substituted indazole-o-glucosides
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
MY147375A (en) * 2005-01-31 2012-11-30 Mitsubishi Tanabe Pharma Corp Indole derivatives
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
TWI418556B (zh) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
NZ577391A (en) * 2006-12-04 2011-11-25 Janssen Pharmaceutica Nv Thienyl-containing glycopyranosyl derivatives as antidiabetics
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
JP5596545B2 (ja) 2007-09-10 2014-09-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｓｇｌｔの阻害物質として有用な化合物の製造方法
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CA2725047A1 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
EP2451797B1 (de) 2009-07-10 2013-04-03 Janssen Pharmaceutica, N.V. Kristallisationsverfahren für 1-(beta-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorphenyl)-2-thienylmethyl]benzol
US9174971B2 (en) * 2009-10-14 2015-11-03 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
KR101931209B1 (ko) 2010-05-11 2018-12-20 얀센 파마슈티카 엔.브이. Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형
AU2012241897C1 (en) 2011-04-13 2017-05-11 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
KR20210034039A (ko) 2018-07-19 2021-03-29 아스트라제네카 아베 다파글리플로진을 사용하는 HFpEF의 치료 방법 및 이를 포함하는 조성물
US20220023252A1 (en) 2020-07-27 2022-01-27 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
EP4315350A1 (de) 2021-04-01 2024-02-07 AstraZeneca UK Limited Systeme und verfahren zur verwaltung von prädiabetes mit einer pharmazeutischen gliflozin-natrium-glucose-cotransport-2-inhibitorzusammensetzung
WO2023144722A1 (en) 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031260A (en) * 1971-05-14 1977-06-21 Nutrilite Products, Inc. Salts of dihydrochalcone derivatives and their use as sweeteners
US3984394A (en) * 1971-05-14 1976-10-05 Nutrilite Products, Inc. Salts of dihydrochalcone derivatives and their use as sweeteners
US4049715A (en) * 1973-10-01 1977-09-20 Sterling Drug Inc. 3-[2-(4-Anisidino)phenyl]-1-phenyl-1-propiophenones and propanols
US4684627A (en) * 1981-09-08 1987-08-04 Leveen Harry H Treatment of cancer with phlorizin and its derivatives
CA1289077C (en) * 1984-08-13 1991-09-17 Harry H. Leveen Treatment of cancer with phlorizin and its derivatives
US5110801A (en) * 1984-08-13 1992-05-05 Leveen Harry H Treatment of acne
US4760135A (en) * 1984-09-06 1988-07-26 University Of Kentucky Research Foundation Phloretin and phlorizin derivative containing compounds
US4665058A (en) * 1985-03-16 1987-05-12 The University Of Kentucky Research Foundation Compositions and method of treatment for sickle cell anemia
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent

Also Published As

Publication number Publication date
EP0684254B1 (de) 1999-03-24
CA2149160A1 (en) 1995-11-12
CA2149160C (en) 2002-01-29
DK0684254T3 (da) 1999-10-11
AU680118B2 (en) 1997-07-17
FI952260A (fi) 1995-11-12
US5830873A (en) 1998-11-03
BR9502016A (pt) 1995-12-12
DE69508463D1 (de) 1999-04-29
FI952260A0 (fi) 1995-05-10
AU1779095A (en) 1995-11-16
IL113581A0 (en) 1995-08-31
CN1121925A (zh) 1996-05-08
ATE178069T1 (de) 1999-04-15
EP0684254A1 (de) 1995-11-29
MY119134A (en) 2005-04-30
GR3029795T3 (en) 1999-06-30
IL113581A (en) 1999-07-14
ES2133614T3 (es) 1999-09-16
KR100318793B1 (ko) 2002-07-04
FI116975B (fi) 2006-04-28
KR950032262A (ko) 1995-12-20
CN1042637C (zh) 1999-03-24

Similar Documents

Publication Publication Date Title
DE69508463D1 (de) Propiophenonderivate und Verfahren zu deren Herstellung
HU9600834D0 (en) Quinazoline derivatives
ATE139232T1 (de) Bizyklische pyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung
MY119350A (en) Propiophenone derivatives and process for preparing the same
DE69601345D1 (de) Propiophenon-Derivate und Verfahren zur ihrer Herstellung
IL113894A0 (en) Oxalylamino-benzofuran- and benzothienyl-derivatives process for their preparation pharmaceutical compositions containing them and their use
AU697679B2 (en) Treatment of tinnitis using neuroprotective agents
ATE131173T1 (de) Fluorierte gallensäure-derivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen daraus.
DE69631609D1 (en) Tricyclische erythromycinderivate
NZ236034A (en) Pharmaceutical compositions containing imidazole derivatives; topical compositions for treating glaucoma
AU5754294A (en) Use of a pregnane derivative
IL125951A (en) A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal
IL113780A (en) Glucopyranoside benzothiophenes process for their preparation and pharmaceutical compositions containing them
ES2196174T3 (es) `derivados de sesquiterpeno de actividad antiviral.
HUT52478A (en) Process for producing glycerin derivatives and pharmaceutical compositions comprising same
AU7424394A (en) 3- or 4-glycosyloxybenzopyran derivatives and antiallergic agents containing the derivatives as active ingredients
IL130052A0 (en) Method of treating glaucoma and ischemic retinopathy
DE69118126D1 (de) Derivate von 10,11,12,13-tetra-hydrodesmycosin, Verfahren zu ihrer Herstellung, und ihre Verwendung zur Herstellung von Arzneimitteln

Legal Events

Date Code Title Description
8364 No opposition during term of opposition